Vibrant

Biopharmaceutical Drug Developmentvibrantx.com

Vibrant Therapeutics is a clinical-stage biotech developing conditional activation, multispecific antibody-based prodrugs for oncology, autoimmune, and CNS diseases via three proprietary platforms (BumbleBee, LogicBee, NeuroBee), with lead program VIB305 advancing in U.S., Australian, and Chinese trials.

Company typePrivate
Founded2019
HeadquartersGuangzhou, China
Headcount51–100
GTM typeB2B
OfferingServices

What Vibrant does

Vibrant Therapeutics is a privately held, venture-backed biotechnology company founded in 2019 that develops conditional activation and targeted delivery multispecific antibody-based prodrugs for oncological, autoimmune, and neurological diseases. The company operates three proprietary platforms — BumbleBee (computational multi-specific antibody engineering), LogicBee (proteomics-based target identification), and NeuroBee (blood-brain-barrier delivery) — designed to work in concert to enable rational design of safer, more effective biotherapeutics. Its lead clinical program, VIB305, is a logic-gated, dual-targeting masked T-cell engager targeting EGFR-positive solid tumors, which received FDA IND acceptance in January 2026 and is being evaluated in clinical trials across the United States, Australia, and China.

The company is dual-headquartered in Cambridge, MA (United States) and Guangzhou, China, with a headcount of 51-100 employees. Leadership comprises Co-CEO & CTO Dr. Larry Wang and Co-CEO Dr. Han Lee (appointed January 2026), supported by SVPs covering antibody discovery, CMC, and operations, plus a dedicated BD lead. Vibrant's revenue model is pre-commercial biopharmaceutical development: it does not yet sell products, and revenue is expected to be generated through future drug commercialization or one-time licensing of assets and technologies, with partnerships actively solicited via [email protected]. The company has raised approximately $100 million in total capital, including a $61 million round in January 2026 that brought in Pfizer Ventures and Apricot Capital as new strategic investors alongside prior backers Bayland Capital, First Principle Venture, HSG, Northern Light Venture Capital, Matrix Partners China, and Redhill Capital.

The go-to-market posture is enterprise-oriented, combining clinical execution (trials run via CROs and medical institutions across three jurisdictions) with a partnership-led business development motion targeting strategic co-development or licensing counterparties in pharma. Customer concentration is by definition not yet observable, as no products are commercialized; the addressable base spans oncology, autoimmune, and CNS patient populations to be served either directly post-approval or through partner-led commercialization.

Vibrant firmographics

Firmographics

Name: Vibrant
Legal name: Vibrant Therapeutics
Website: https://vibrantx.com
Company type: Private
Founded year: 2019
Operating status: Operating
Headcount range: 51–100 employees
Short description: Vibrant Therapeutics is a clinical-stage biotech developing conditional activation, multispecific antibody-based prodrugs for oncology, autoimmune, and CNS diseases via three proprietary platforms (BumbleBee, LogicBee, NeuroBee), with lead program VIB305 advancing in U.S., Australian, and Chinese trials.
Ownership category
akta.pro rank

Vibrant industry classification

Industry

Product category: Biopharmaceutical Drug Development
NAICS: Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC: Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry: Bispecific & Multispecific Antibodies (HLAAAAAF)
akta.pro secondary industry: Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

Biotherapeutic drug development
Antibody engineering platforms
Oncology therapeutics pipeline
Autoimmune disease drugs
CNS drug delivery

Where Vibrant is headquartered

Location

Headquarters

HQ city: Guangzhou
HQ country: China
HQ region: Asia

Offices2 records

Markets served

Vibrant business model

Business model

GTM type: B2B
Offering type: Services
Cost components: Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

Biopharmaceutical Development: Developing biotherapeutics for oncological, autoimmune, and neurological diseases. Revenue will be generated through drug commercialization upon regulatory approval. Current programs include VIB305 for EGFR-positive solid tumors.

Go-to-market motion1 record

Marketing channels1 record

Vibrant product offering

Product offering

Core offering

Vibrant Therapeutics develops conditional activation and targeted delivery multispecific antibody-based prodrugs for oncological, autoimmune, and neurological diseases. Its offering is anchored by three proprietary platforms — BumbleBee (computational antibody engineering), LogicBee (proteomics-based target identification), and NeuroBee (blood-brain-barrier delivery) — and a lead clinical asset, VIB305, a logic-gated, dual-targeting masked T-cell engager for EGFR-positive solid tumors.

Product overview

Vibrant Therapeutics develops a unified portfolio of conditional activation and targeted delivery multispecific antibody-based prodrugs for oncological, autoimmune, and neurological diseases. The company's offerings center on VIB305, a lead program for EGFR-positive solid tumors, supported by three proprietary technology platforms: BumbleBee (computational multi-specific antibody engineering), LogicBee (proteomics-based target identification), and NeuroBee (blood-brain-barrier delivery). These platforms work together to enable rational design, precise disease targeting, and CNS delivery of biotherapeutics.

Differentiator

Problem solved

Functional benefit

Brands

BumbleBee Platform: Advanced computing and multi-specific antibody engineering platform for streamlined biotherapeutic discovery
LogicBee Platform
NeuroBee Platform
VIB305

Products and services

VIB305 A logic-gated, dual-targeting masked T-cell engager for treatment of EGFR-positive solid tumors; Vibrant Therapeutics' lead clinical program, which received FDA IND acceptance and enables initiation of U.S. clinical studies.
BumbleBee Platform Computational multi-specific antibody engineering platform that combines advanced computing with multi-specific antibody engineering to streamline biotherapeutic discovery and rational design. Offered to partners for collaboration regarding assets and technologies.
LogicBee Platform Proteomics-based target identification platform that identifies key proteins differing between healthy and diseased tissues, enabling the design of biotherapeutics that precisely target diseases.
NeuroBee Platform

Quantifiable outcome

VIB305 (logic-gated, dual-targeting masked T-cell engager) received FDA IND acceptance

Companies that use Vibrant

Customer profile

Segments3 records

Ideal customer profiles1 record

Vibrant technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vibrant partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

Prospective PartnersminorStrategic or Co-development PartnerVibrant Therapeutics is open to partnerships and collaborations regarding assets and technologies. The company seeks strategic partners for co-development of biotherapeutics for oncological, autoimmune, and neurological diseases.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Vibrant competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Vibrant financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vibrant leadership team

Management profile

Number of profiles

Profiles6 records

Vibrant funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vibrant M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vibrant

What does Vibrant do?

Is Vibrant a public or private company?

Vibrant is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vibrant founded?

Vibrant was founded in 2019. It employs 51 to 100 people.

Where is Vibrant based?

Vibrant is headquartered in Guangzhou, China, in the Asia region.

How does Vibrant make money?

One revenue line is on record: biopharmaceutical Development.

Does Vibrant have an API?

No public API is recorded for Vibrant.

What industry is Vibrant in?

Vibrant's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 541714 and its SIC code is 2836.